Recent Advances in the Pharmacological Management of Atrial Fibrillation

Janelle Y. Gooden, Brian D. Powell, Clement O. Akogyeram, Rowlens M. Melduni

Research output: Contribution to journalArticlepeer-review


Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.

Original languageEnglish (US)
Pages (from-to)e118-e138
JournalAmerican journal of therapeutics
Issue number1
StatePublished - Jan 1 2016


  • atrial fibrillation
  • new oral anticoagulants
  • oral factor Xa inhibitors
  • oral thrombin inhibitors
  • stroke prevention

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Recent Advances in the Pharmacological Management of Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this